person · Reporting owner
LaBella Nicholas A. Jr.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZyVersa Therapeutics, Inc.ZVSA · Entity 8639 | Chief Scientific Officer | December 12, 2022 | December 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZyVersa Therapeutics, Inc.
Report date December 12, 2022 · Filed December 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,094 |
Reported balance
After 2022-12-12 transaction · row 1
1 source rowRow 1 · 2022-12-12 · Grant · Acquired 18,094 · Balance 18,094 F1: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2024-04-11 | Direct | 19,854 |
Reported balance
After 2022-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-12 · Grant · Acquired 19,854 · Balance 19,854 F2: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2025-06-09 | Direct | 39,709 |
Reported balance
After 2022-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-12 · Grant · Acquired 39,709 · Balance 39,709 F3: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2027-10-30 | Direct | 59,563 |
Reported balance
After 2022-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-12 · Grant · Acquired 59,563 · Balance 59,563 F4: 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2029-04-02 | Direct | 39,708 |
Reported balance
After 2022-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-12 · Grant · Acquired 39,708 · Balance 39,708 F5: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2031-02-08 | Direct | 29,781 |
Reported balance
After 2022-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-12 · Grant · Acquired 29,781 · Balance 29,781 F6: The option vests in 3 equal annual installments commencing on February 8, 2022. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2032-01-28 | Direct | 29,781 |
Reported balance
After 2022-12-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-12 · Grant · Acquired 29,781 · Balance 29,781 F7: The option vests in 3 equal annual installments commencing on January 28, 2023. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2027-12-12 | Direct | 18,094 |
Reported balance
After 2022-12-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-12 · Grant · Acquired 18,094 · Balance 18,094 F8: The warrant is immediately exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.
F2: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.
F3: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016.
F4: 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
F5: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
F6: The option vests in 3 equal annual installments commencing on February 8, 2022.
F7: The option vests in 3 equal annual installments commencing on January 28, 2023.
F8: The warrant is immediately exercisable in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantWarrant (right to buy) · Derivative | 18,094 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 8 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,094 Underlying: Common Stock · 18,094 shares Expires 2027-12-12 F8 · derivative.exercise_date: The warrant is immediately exercisable in full. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 29,781 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 7 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,781 Underlying: Common Stock · 29,781 shares Expires 2032-01-28 F7 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on January 28, 2023. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 29,781 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 6 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,781 Underlying: Common Stock · 29,781 shares Expires 2031-02-08 F6 · derivative.exercise_date: The option vests in 3 equal annual installments commencing on February 8, 2022. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 39,708 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 5 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,708 Underlying: Common Stock · 39,708 shares Expires 2029-04-02 F5 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 59,563 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 4 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,563 Underlying: Common Stock · 59,563 shares Expires 2027-10-30 F4 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 39,709 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 3 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,709 Underlying: Common Stock · 39,709 shares Expires 2025-06-09 F3 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantStock Options (right to buy) · Derivative | 19,854 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · derivative · entry 2 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,854 Underlying: Common Stock · 19,854 shares Expires 2024-04-11 F2 · derivative.exercise_date: 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 19:31 UTC | ZyVersa Therapeutics, Inc. ZVSA · Entity 8639 | GrantCommon Stock | 18,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-035483 · ownership.xml · nonDerivative · entry 1 LaBella Nicholas A. Jr. · CIK 0001487698 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,094 F1 · price: Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.